Search results for "Insulin-like growth factor 1 receptor"

showing 10 items of 13 documents

Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma

2020

Contains fulltext : 235640.pdf (Publisher’s version ) (Closed access) Genome-wide association studies (GWAS) of esophageal adenocarcinoma (EAC) and its precursor, Barrett's esophagus (BE), have uncovered significant genetic components of risk, but most heritability remains unexplained. Targeted assessment of genetic variation in biologically relevant pathways using novel analytical approaches may identify missed susceptibility signals. Central obesity, a key BE/EAC risk factor, is linked to systemic inflammation, altered hormonal signaling and insulin-like growth factor (IGF) axis dysfunction. Here, we assessed IGF-related genetic variation and risk of BE and EAC. Principal component analys…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyEsophageal NeoplasmsMedizinSingle-nucleotide polymorphismGenome-wide association studyBiologyAdenocarcinomaPolymorphism Single NucleotideReceptor IGF Type 103 medical and health sciencesBarrett Esophagus0302 clinical medicineRisk FactorsSomatomedinsInternal medicineGenetic variationmedicineBiomarkers TumorSNPHumansGenetic Predisposition to DiseaseRisk factorGerm-Line MutationCancer Biomarkers and Molecular EpidemiologyInsulin-like growth factor 1 receptorGenetic associationAgedGeneral MedicineMiddle Agedmedicine.diseaseRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biology030220 oncology & carcinogenesisBarrett's esophagusFemaleHuman medicineCarrier ProteinsGenome-Wide Association StudySignal TransductionCarcinogenesis
researchProduct

Bisphenolic compounds alter gene expression in MCF-7 cells through interaction with estrogen receptor α

2020

Plasticizers released from microplastic are increasingly viewed with concern. While adverse health effects induced by bisphenol A and its analogues on marine animals are well documented in the literature, the endocrine potential of bisphenolic compounds on human health remains elusive. We applied next generation sequencing (NGS) with the estrogen receptor α (ERα) positive human breast cancer cell line MCF-7 treated with 17-β-estradiol (E2), bisphenol A (BPA), bisphenol B (BPB), bisphenol Z (BPZ) and tetramethyl bisphenol A (4MeBPA). We used molecular docking, microscale thermophoresis, ERα activation assay, and cell cycle experiments on MCF-7 and ERα overexpressing HEK293 cells to verify th…

0301 basic medicineendocrine systemBisphenolDown-RegulationGene ExpressionEstrogen receptorBreast NeoplasmsEndocrine DisruptorsToxicologyCell Line03 medical and health sciences0302 clinical medicinePhenolsPlasticizersBCAS3Cell Line TumorHumansBenzhydryl CompoundsCell ProliferationInsulin-like growth factor 1 receptorPharmacologyEstradiolChemistryCell growthEstrogen Receptor alphaEstrogensCell cycleUp-RegulationHEK293 Cells030104 developmental biologyPRKCDMCF-7030220 oncology & carcinogenesisMCF-7 CellsCancer researchFemalehormones hormone substitutes and hormone antagonistsSignal TransductionToxicology and Applied Pharmacology
researchProduct

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical…

2014

Abstract Purpose: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin–like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination. Experimental Design: In vitro and in vivo models, and a phase I study in which patients with advanced cancer received ridaforolimus (10–40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week) were explored. Results: Preclinical studies demonstrated enhanced pathway inhibition with ridaforolimus and dalotuzumab. With 87 patients treated in the phase I study, main dose-limiting toxicities (DLT) of the combination were p…

AdultCancer ResearchPhases of clinical researchBreast NeoplasmsPharmacologyAntibodies Monoclonal HumanizedArticleReceptor IGF Type 1Ridaforolimuschemistry.chemical_compoundBreast cancerIn vivoAntineoplastic Combined Chemotherapy ProtocolsMedicineAnimalsHumansPI3K/AKT/mTOR pathwayInsulin-like growth factor 1 receptorAgedSirolimusDalotuzumabbusiness.industryTOR Serine-Threonine KinasesAntibodies MonoclonalReceptors SomatomedinMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysOncologychemistryMonoclonalbusinessSignal TransductionClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Subtype-specific endothelin-A and endothelin-B receptor desensitization correlates with differential receptor phosphorylation.

1998

In the rat cardiovascular system endothelin-1 (ET-1) elicits prolonged physiologic responses mediated by the ET A receptor, whereas the effects mediated by the ET B receptor are transient. The molecular mechanisms for the subtype-specific responses are not yet clear. However, post-translational modifications such as phosphorylation and palmitoylation may play an important role. In Sf9 cells overexpressing the human ET A and ET B receptors, both subtypes are palmitoylated. However, only the ET B but not the ET A receptor is phosphorylated in a ligand-dependent manner. Because phosphorylation is believed to play an important role in ligand-dependent receptor inactivation, we analyzed whether …

Endothelin Receptor Antagonistsmedicine.medical_specialtyTropomyosin receptor kinase BCHO CellsBiologyEstrogen-related receptor alphaInternal medicineCricetinaemedicineEnzyme-linked receptorAnimalsHumansCloning MolecularPhosphorylationReceptorProtease-activated receptor 2Insulin-like growth factor 1 receptorPharmacologyReceptors EndothelinInterleukin-13 receptorReceptor Endothelin AReceptor Endothelin BCell biologyRatsInterleukin 10KineticsEndocrinologyCardiology and Cardiovascular MedicineSignal TransductionJournal of cardiovascular pharmacology
researchProduct

2019

The insulin-like growth factor (IGF) pathway plays an important role in several brain tumor entities. However, the lack of inhibitors crossing the blood–brain barrier remains a significant obstacle for clinical translation. Here, we targeted the IGF pathway using ceritinib, an off-target inhibitor of the IGF1 receptor (IGF1R) and insulin receptor (INSR), in a pediatric patient with an unclassified brain tumor and a notch receptor 1 (NOTCH1) germline mutation. Pathway analysis of the tumor revealed activation of the sonic hedgehog (SHH), the wingless and integrated-1 (WNT), the IGF, and the Notch pathway. The proliferation of the patient tumor cells (225ZL) was inhibited by arsenic trioxide …

LinsitinibbiologyCeritinibChemistrymedicine.medical_treatmentGrowth factorOrganic ChemistryWnt signaling pathwayNotch signaling pathwayGeneral MedicineCatalysisComputer Science ApplicationsInorganic ChemistryInsulin-like growth factorInsulin receptorchemistry.chemical_compoundmedicineCancer researchbiology.proteinPhysical and Theoretical ChemistryMolecular BiologySpectroscopyInsulin-like growth factor 1 receptormedicine.drugInternational Journal of Molecular Sciences
researchProduct

Organophosphate ester tri-o-cresyl phosphate interacts with estrogen receptor α in MCF-7 breast cancer cells promoting cancer growth

2020

Plastic in the ocean degrades to microplastic, thereby enhancing the leaching of incorporated plasticizers due to the increased particle surface. The uptake of microplastic-derived plasticizers by marine animals and the subsequent entry in the food chain raises concerns for adverse health effects in human beings. Frequently used plasticizers as the organophosphate ester tri-o-cresyl phosphate (TOCP) are known to affect the male reproductive system. However, the overall endocrine potential of TOCP and the underlying molecular mechanisms remain elusive as yet. In this study, we investigated the molecular effects of TOCP on estrogen receptor α (ERα)-transfected HEK-ESR1 cells and the human bre…

MaleModels Molecular0301 basic medicineAngiogenesisEstrogen receptorBreast NeoplasmsEndocrine DisruptorsSLC7A11TransfectionToxicology03 medical and health sciences0302 clinical medicinePlasticizersHumansNeoplasm InvasivenessNeoplasm MetastasisInsulin-like growth factor 1 receptorPharmacologyNeovascularization PathologicbiologyChemistryCell CycleEstrogen Receptor alphaHigh-Throughput Nucleotide SequencingCell cycleCell biologyGene Expression Regulation NeoplasticMolecular Docking SimulationTritolyl PhosphatesHEK293 Cells030104 developmental biologyPRKCDMCF-7030220 oncology & carcinogenesisMCF-7 Cellsbiology.proteinRNAFemaleEstrogen receptor alphaToxicology and Applied Pharmacology
researchProduct

The Insulin Receptor Substrate 1 (Irs1) in Intestinal Epithelial Differentiation and in Colorectal Cancer

2012

Colorectal cancer (CRC) is associated with lifestyle factors that affect insulin/IGF signaling, of which the insulin receptor substrate 1 (IRS1) is a key transducer. We investigated expression, localization and pathologic correlations of IRS1 in cancer-uninvolved colonic epithelium, primary CRCs with paired liver metastases and in vitro polarizing Caco2 and HT29 cells. IRS1 mRNA and protein resulted higher, relative to paired mucosa, in adenomas of familial adenomatous polyposis patients and in CRCs that overexpressed c-MYC, ß-catenin, InsRß, and IGF1R. Analysis of IRS1 immunostaining in 24 cases of primary CRC with paired colonic epithelium and hepatic metastasis showed that staining inten…

MalePathologyAnatomy and PhysiologySettore MED/06 - Oncologia MedicaMetastasisIntestinal mucosaInsulin Signaling CascadeMolecular Cell BiologyGastrointestinal CancersBasic Cancer ResearchInsulinIntestinal MucosaInsulin-like Growth FactorCOLON-CARCINOMA-CELLS; GROWTH-FACTOR RECEPTOR; BETA-CATENIN; FACTOR-I; IGF-I; NUCLEAR TRANSLOCATION; ADENOMATOUS POLYPOSIS; STEM-CELL; EXPRESSION; MUTATIONSMultidisciplinarybiologyChemistryQLiver NeoplasmsRCell PolarityCell DifferentiationSignaling CascadesGene Expression Regulation NeoplasticProtein Transportmedicine.anatomical_structureOncologyMedicineFemaleColorectal NeoplasmsHT29 CellsResearch ArticleSignal TransductionAdultendocrine systemmedicine.medical_specialtyColonScienceIRS1 IGF1R colorectal cancerEndocrine SystemGastroenterology and HepatologySignaling PathwaysFamilial adenomatous polyposisHT29 CellsmedicineHumansBiologyAgedInsulin-like growth factor 1 receptorEndocrine Physiologymedicine.diseasedigestive system diseasesEpitheliumIRS1Insulin receptorInsulin Receptor Substrate Proteinsbiology.proteinCancer researchCaco-2 CellsImmunostainingInsulin-Dependent Signal Transduction
researchProduct

Effect of circulating growth hormone on muscle IGF-I protein concentration in female mice with growth hormone receptor gene disruption.

2009

Growth hormone (GH) is a potent secretague for circulating insulin-like growth factor-I (IGF-I). The purpose of this study was to examine the effect of circulating GH on muscle IGF-I protein expression using GH transgenic animal models. Three different models were used: mice that overexpress bovine GH (bGH; n=10), mice without a functional GH receptor (GHR-/-; n=10), and wildtype mice (n=10). All mice were 16-week old females and each group differed in their basic phenotypic characteristics. Immediately after euthanization the triceps surae muscle group (soleus, plantaris, and gastrocnemius muscles) was removed. IGF-I was extracted from the muscle with an acid-ethanol solution (12.5% 2N hyd…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismTransgenemedicine.medical_treatmentMice TransgenicGrowth hormone receptorBiologyMiceEndocrinologyTriceps surae muscleInternal medicinemedicineAnimalsInsulin-Like Growth Factor IReceptorMuscle SkeletalInsulin-like growth factor 1 receptorMice KnockoutGrowth factorRadioimmunoassayReceptors SomatotropinMice Inbred C57BLEndocrinologyGrowth HormoneCattleFemaleHormoneGrowth hormoneIGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
researchProduct

TRTH-08. HIGH GRADE NEUROEPITHELIAL TUMOR OF THE CENTRAL NERVOUS SYSTEM WITH BCOR ALTERATION IS SENSITIVE TO IGF1R INHIBITION

2017

High grade neuroepithelial tumor of the central nervous system with BCOR alteration (CNS HGNET-BCOR) is a recently described new tumor entity which was formerly diagnosed with diverse histological diagnoses, for example as ependymoma. This tumor predominantly affects children and has a dismal prognosis. No standard therapies for this entity exist so far. Recently we described the activation of the Sonic hedgehog (SHH) and the WNT signaling pathway in this tumor and described a primary cell culture (PhKh1) isolated from a skull metastasis of a seven years old patient. We also detected a high expression of IGF2, which is known to be required for SHH signaling in medulloblastoma. IGF2 signals …

MedulloblastomaEpendymomaCancer Researchanimal structuresCell growthCentral nervous systemWnt signaling pathwayBiologymedicine.diseaseNeuroepithelial cellAbstractsmedicine.anatomical_structureOncologyCell culturemedicineCancer researchNeurology (clinical)Insulin-like growth factor 1 receptor
researchProduct

49P Targeting IGF1R in osteosarcoma

2020

Oncologybusiness.industryCancer researchMedicineOsteosarcomaHematologybusinessmedicine.diseaseInsulin-like growth factor 1 receptorAnnals of Oncology
researchProduct